REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Regulatory Updates

FDA actions, peptide reclassifications, and industry news

REGULATORY

RFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026

TRENDING

Hexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026

UPDATE

Semaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025

REGULATORY

BPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pending

EVENT

pep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CA

FDA

FDA advisory committee meetings scheduled: late July 2026

FDA Drug Database

Search FDA-approved peptide drugs

Legal Disclaimer

Research-only usage guidelines